Legend Biotech
Market cap $3.12B 194.0M shares (vendor count, Nov 18, 2026) × $16.11 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2026-03-20
- Legend Biotech corporate update2026Legend Biotech corporate update, 2026, routine
- anito-cel Arcellx PDUFA dateDec 23, 2026anito-cel Arcellx PDUFA date, Dec 23, 2026, thesis-defining
- Janssen Funding Advance corporate update~1Q 2027Janssen Funding Advance corporate update, ~1Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (17 active programs)
LB1908
LB2102
LUCAR-G39D
GCC CAR-T
LB2401
LB2402
LB2403
LB2502
LB2404D
- Undisclosed indication
LB2405
- Undisclosed indication
LB2302
LB2303
LB2501
Technology platforms
TaVec
Proprietary in vivo cell engineering platform using an engineered, replication-incompetent lentiviral vector designed to selectively transduce T cells in vivo, enabling off-the-shelf CAR-T generation directly within the patient; focus area: B-cell malignancies including B-cell non-Hodgkin lymphoma
Targets: CD19, CD20
Capital (as filed)
- Cash
- $902M cash and cash equivalents · Dec 31, 2025 (20-F)
- Operating cash flow
- −$25.1M annual ÷ 4, year to Dec 31, 2025 (20-F)
- As stated in coverage
- $853M cash per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (4)
- 2026-11-11 UPDATE: Legend Biotech (LEGN) - The US Engine Went Flat 🔒 Paid
- 2026-09-16 UPDATE: Legend Biotech (LEGN) - They Hired a Commercial Operator 🔒 Paid
- 2026-08-12 UPDATE: Legend Biotech (LEGN) - The Margin Line Answers Back 🔒 Paid
- 2026-07-29 Legend Biotech (LEGN) — Scientific Deep Dive for CARVYKTI® (cilta-cel) and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (4 calls)
Every verdict Biotech Distilled has published on Legend Biotech, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-07-29 Watch Legend Biotech (LEGN) — Scientific Deep Dive for CARVYKTI® (cilta-cel) and Pipeline Products Best-in-class science but Legend owns only half the economics, collaboration gross margin fell 21 points year over year, J&J is clawing back $266M, BMS is litigating the European franchise, and all date-certain catalysts in the next twelve months belong to a competitor.
- 2026-08-12 Speculative buy speculative UPDATE: Legend Biotech (LEGN) - The Margin Line Answers Back Q2 collaboration gross margin snapped back to 58.3% from 41.2%, validating the one-time explanation, and the J&J clawback is two-thirds retired, but the competitive question remains open with anito-cel's PDUFA on December 23.
- 2026-09-16 Speculative buy speculative UPDATE: Legend Biotech (LEGN) - They Hired a Commercial Operator Hiring a permanent commercial-operator CEO retires the interim-CEO overhang, but the UPC action against the European franchise and the December 23 anito-cel PDUFA remain unresolved, keeping the position speculative and staged.
- 2026-11-11 Hold UPDATE: Legend Biotech (LEGN) - The US Engine Went Flat US CARVYKTI sales went flat quarter over quarter at $472M before anito-cel's arrival, undermining the growth thesis even as margins held and the J&J clawback neared completion, so existing holders keep a core position but new money has little reason to rush in before the December 23 PDUFA.
- Long call · opened Aug 12, 2026 at $20.65 · -22.0% vs XBI -8.9% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (35)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 28, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseLegend Biotech Reports Third Quarter 2026 Results and Recent Highlights→ BD updateSummary on the 6-K
- Nov 10, 20266-KForeign issuer report · EX-99.1→ BD updateQ3 earnings: CARVYKTI hit ~$710M in net trade sales (+36% YoY), collaboration gross margin held at ~58.4%, and the J&J Funding Advance is now down to $44.1M from $319.1M — the cash-flow inflection is essentially complete. FDA also cleared the LB2501 IND. Yet the stock cratered 16% on the print, and the reason matters: December 23 is six weeks away.
- Nov 4, 2026ReleaseLegend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
- Nov 4, 20266-KForeign issuer report · EX-99.1 PRESS RELEASE
- Oct 27, 2026ReleaseLegend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
- Oct 15, 2026ReleaseLegend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
- Oct 15, 20266-KForeign issuer report · EX-99.1 PRESS RELEASE
- Oct 13, 20266-KForeign issuer report
- Oct 1, 2026ReleaseLegend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
- Sep 25, 2026ReleaseLegend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
- Sep 25, 20266-KForeign issuer report · EX-99.1 PRESS RELEASEBD extracted 1 program update from this document → LEGN pipeline
- Sep 24, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Sep 15, 2026ReleaseLegend Biotech Appoints Ingrid Zhang as Chief Executive Officer→ BD updateSummary on the 6-K
- Sep 15, 20266-KForeign issuer report · EX-99.1 PRESS RELEASE→ BD updateLegend has filled its CEO vacancy — Ingrid Zhang, former CCO of Novartis International, takes the helm today, resolving the leadership overhang flagged in both the deep dive and the August 11 update, while the stock sits 19% below that update's close ahead of the December 23 anito-cel PDUFA.
- Sep 14, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Sep 10, 2026ReleaseLegend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual MeetingBD extracted 1 program update from this document → LEGN pipeline
- Sep 1, 2026ReleaseLegend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
- Aug 18, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Aug 11, 2026ReleaseLegend Biotech Reports Second Quarter 2026 Results and Recent HighlightsBD extracted 2 program updates from this document → LEGN pipeline
- Aug 11, 20266-KForeign issuer report · EX-99.1
- Aug 6, 20266-KForeign issuer report
- Jul 28, 2026ReleaseLegend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
- Jul 27, 20266-KForeign issuer report
- Jul 15, 20266-KForeign issuer report
- Jun 22, 20266-KForeign issuer report · EX-99.1
- Jun 18, 2026424B5Prospectus supplement (offering)
- Jun 17, 2026424B5Prospectus supplement (offering)
- Jun 15, 20266-KForeign issuer report · EX-99.1 PRESS RELEASE
- Jun 2, 20266-KForeign issuer report · EX-99.1 PRESS RELEASE
- Jun 1, 20266-KForeign issuer report · EX-99.1 PRESS RELEASE
- May 21, 20266-KForeign issuer report · EX-99.1 PRESS RELEASE
- May 12, 20266-KForeign issuer report · EX-99.1
- Apr 14, 20266-KForeign issuer report
- Mar 10, 20266-KForeign issuer report · EX-99.1 PRESS RELEASE
- Mar 10, 202620-FAnnual report (foreign)
4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Oct 7, 2026S-8Employee plan registration
- Aug 6, 2026SCHEDULE 13G/A13G amendment
- Jun 17, 2026F-6EFF-6EF